A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer.

ABSTRACT:

Purpose

Previous studies suggest that a cumulative cisplatin dose of 200 mg/m² might be adequate in the intensity-modulated radiation therapy (IMRT) era for locoregionally advanced nasopharyngeal carcinoma (LANPC). However, two cycles of once-every-3-weeks cisplatin at 100 mg/m² has never been prospectively compared with standard once-a-week cisplatin regimen.

Patients and methods

This trial was conducted at three hospitals from 2011 to 2016. Patients who met the eligibility criteria were recruited (ChiCTR-TRC-12001979) and randomly assigned (1:1) via a computer-generated sequence to receive once-every-3-weeks cisplatin at 100 mg/m² for two cycles or once-a-week cisplatin at 40 mg/m² for six cycles concurrently with IMRT. Primary e

SUBMITTER: Xia WX 

PROVIDER: S-EPMC8974421 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature